Axcella gains as long COVID treatment helps some patients in small trial

Axcella Health

02/08/2022 11:26

** Axcella Health's shares  AXLA.O  rose nearly 12% to $2.17
premarket
    ** AXLA's long COVID-19 treatment helps some patients in a
small trial of 41 patients  urn:newsml:reuters.com:*:nL1N2ZD1LH
    ** Physical fatigue scores returned to normal levels after
28 days of treatment for 3 of 21 patients who received the drug,
AXA1125
    ** However, mid-stage trial fails main goal of restoring
normal function of mitochondria - the energy factories of cells
    ** 6 of 7 brokerages rate the stock "buy" or higher, 1
"sell"; their median PT is $9
    ** Stock had fallen ~7% YTD, up to last close

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))